KCM
NBIX icon

Kennedy Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Kennedy Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.33M Sell
49,437
-5,618
-10% -$833K 0.15% 237
2026
Q1 		$7.25M Buy
55,055
+8,004
+17% +$1.06M 0.15% 227
2025
Q4 		$6.67M Sell
47,051
-9,218
-16% -$1.34M 0.14% 232
2025
Q3 		$7.9M Buy
56,269
+2,791
+5% +$378K 0.17% 215
2025
Q2 		$6.72M Sell
53,478
-4,176
-7% -$479K 0.16% 223
2025
Q1 		$6.38M Buy
57,654
+21,542
+60% +$2.73M 0.15% 231
2024
Q4 		$4.93M Buy
36,112
+5,093
+16% +$630K 0.11% 332
2024
Q3 		$3.57M Buy
31,019
+2,539
+9% +$348K 0.08% 388
2024
Q2 		$3.92M Sell
28,480
-4,756
-14% -$652K 0.08% 374
2024
Q1 		$4.58M Buy
33,236
+11,850
+55% +$1.62M 0.09% 343
2023
Q4 		$2.82M Sell
21,386
-30,185
-59% -$3.47M 0.06% 424
2023
Q3 		$5.8M Sell
51,571
-5,094
-9% -$536K 0.14% 257
2023
Q2 		$5.34M Buy
56,665
+10,032
+22% +$980K 0.12% 278
2023
Q1 		$4.72M Buy
46,633
+23,673
+103% +$2.46M 0.14% 271
2022
Q4 		$2.74M Sell
22,960
-925
-4% -$108K 0.08% 377
2022
Q3 		$2.54M Buy
23,885
+19,899
+499% +$2.02M 0.07% 384
2022
Q2 		$389K Buy
+3,986
New +$368K 0.01% 561

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kennedy Capital Management's NBIX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 10% in Q2 2026, selling an estimated $833K and leaving 49,437 shares worth $8.33M. The position accounts for 0.15% of the portfolio, ranked #237.

Kennedy Capital Management first reported a position in NBIX in Q2 2022 and has held it in 17 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Kennedy Capital Management held 49,437 shares of Neurocrine Biosciences worth $8.33M as of Q2 2026.
  • Kennedy Capital Management sold 5,618 Neurocrine Biosciences shares in Q2 2026, an estimated $833K.
  • Neurocrine Biosciences made up 0.15% of Kennedy Capital Management's portfolio in Q2 2026, its #237 holding.
  • Kennedy Capital Management first reported a position in Neurocrine Biosciences in Q2 2022 and has held it in 17 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.